广东药科大学学报2017，Vol.33Issue(5)：671-676,6.DOI:10.16809/j.cnki.2096-3653.2017061401
恩替卡韦和阿德福韦酯治疗慢性乙型肝炎的真实世界效果评价
Evaluation of the efficacy of entecavir and adefovir dipivoxil in the treatment of chronic hepatitis B based the real world study
摘要
Abstract
Objective To study the efficacy of entecavir ( ETV ) and adefovir dipivoxil ( ADV ) in the treatment of chronic hepatitis B based on the real world study. Methods A total of 427 patients with chronic hepatitis B treated with ETV or ADV were retrospectively collected from January 2008 to December 2015 at Guangzhou Eighth People's Hospital. HBV DNA, HBeAg and ALT in patients were measured before and after ADV or ETV treatment. Meantime, HBV DNA negative conversion rate, HBeAg seroconversion rate and ALT normal rate were analyzed. The survival analysis method was used to compare the efficacy of ADV and ETV treatment. Results Both in HBeAg positive and negative groups, the HBV DNA negative conversion rate in patients was higher in the ETV group than that in the ADV group. In HBeAg (+) subgroup, the HBeAg seroconversion rate was also higher in the ETV group. The ALT normalization rate in the ETV group was different from that in the ADV group at the 3rd and 18th months. In HBeAg (-) subgroup, there was no significant difference in ALT normalization rate between two treatment groups. The HBV DNA response rates in both HBeAg positive and negative patients were different between two treatment groups by COX multivariate analysis. Conclusion ETV is superior to ADV in the treatment of chronic hepatitis B patients with HBeAg positive or negative condition.关键词
慢性乙型肝炎/真实世界/ETV/ADVKey words
chronic hepatitis B/real world/ETV/ADV分类
医药卫生引用本文复制引用
王莹,林畅琪,李伟南,郜艳晖,贾卫东,李粤平,杨翌,周舒冬..恩替卡韦和阿德福韦酯治疗慢性乙型肝炎的真实世界效果评价[J].广东药科大学学报,2017,33(5):671-676,6.基金项目
国家自然科学基金资助(No.71573059) （No.71573059）
广东省公益研究与能力建设项目资助(2014A020212302) （2014A020212302）
